The problem with this and the nnt gatekeeping is that personalized medicine will always require stepping away from massive double blind randomized placebo contr

The problem with this and the nnt gatekeeping is that personalized medicine will always require stepping away from massive double blind randomized placebo controlled multiple meta study levels of evidence. From a patient perspective it feels a lot like economics largely determine medical outcomes.